Quanta has raised $43m in a series B round for the launch of its advanced haemodialysis system, bringing the total raised by the company to $57.3m.

Hepatitis treatment developer Myr raised the cash from High-Tech Gruenderfonds, which previously invested in 2011, and Russian government-backed Maxwell Biotech Fund.

Cambridge life sciences spin-out Epigenetix raises $5.5m in series A.

NantBioScience, a biopharmaceutical firm with links to Colorado University, raises $25m and looks for a total $100m.

Imago BioSciences, which is working on treatments for orphan diseases, has raised $26.5m in a Merck and Amgen-backed series A round.

Napo Pharmaceuticals-backed pet medicine developer Jaguar Animal Health is set to raise $40.4m if it floats at the middle of its range.

Digital health accelerator Rock Health has launched its third and biggest fund with investment from healthcare consortium Kaiser Permanente.

The Johnson & Johnson-backed small protein-based treatment developer raised $102m two weeks after initially suspending the initial public offering due to market conditions.

Biopharmaceutical company Aileron Therapeutics, which is backed by Roche, Novartis, Eli Lilly and GlaxoSmithKline, has extended its series E round to $48m.